Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment.
10.1016/j.apsb.2021.01.009
- Author:
Junmei SHANG
1
;
Shurong MA
1
;
Caixia ZANG
1
;
Xiuqi BAO
1
;
Yan WANG
1
;
Dan ZHANG
1
Author Information
1. Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- Keywords:
COMT;
CYP51;
FLZ;
Gut microbiota;
Parkinson's disease
- From:
Acta Pharmaceutica Sinica B
2021;11(5):1213-1226
- CountryChina
- Language:English
-
Abstract:
The gut microbiota plays an important role in regulating the pharmacokinetics and pharmacodynamics of many drugs. FLZ, a novel squamosamide derivative, has been shown to have neuroprotective effects on experimental Parkinson's disease (PD) models. FLZ is under phase Ⅰ clinical trial now, while the underlying mechanisms contributing to the absorption of FLZ are still not fully elucidated. Due to the main metabolite of FLZ was abundant in feces but rare in urine and bile of mice, we focused on the gut microbiota to address how FLZ was metabolized and absorbed.
